Hypothesis

We propose that mitochondrial DNA (mtDNA) release into the cytosol drives aging not merely by inflammation but by directly reprogramming nuclear chromatin through the cGAS-STING pathway, rendering the nuclear genome a downstream passenger rather than a primary driver.

Background

Recent work shows mtDNA efflux activates cGAS-STING, leading to NF-κB signaling and SASP production[1]. Meanwhile, studies demonstrate that mtDNA mutation load alone fails to recapitulate respiratory decline or aging phenotypes[3], suggesting the release event, not mutational burden, is critical. However, the link between cytosolic mtDNA and nuclear epigenetic state remains unexplored.

Mechanistic Insight

When mtDNA accesses the cytosol, cGAS synthesizes 2'-3'-cGAMP, activating STING. STING signaling can phosphorylate and activate IRF3, but also recruits TBK1 to phosphorylate histone H2AX and modulate chromatin remodelers such as CHD4 and SIRT1. We hypothesize that chronic, low‑level STING activity in senescent cells shifts the balance toward heterochromatin loss at lamina‑associated domains (LADs) and promotes a distinct epigenetic signature characterized by reduced H3K9me3 and increased H3K27ac at pro‑inflammatory loci. This epigenetic drift would then reinforce SASP expression, creating a feed‑forward loop where mtDNA release perpetuates nuclear reprogramming.

Testable Predictions

1. Inhibiting mtDNA release (e.g., via BAX/BAK knockdown or mitochondrial permeability transition pore blockers) will prevent STING‑dependent histone modifications and slow epigenetic clock advancement in aged mice.
2. Genetic ablation of cGAS or STING in senescent fibroblasts will rescue heterochromatin markers at LADs without altering mtDNA mutation load.
3. Inducing controlled mtDNA release in young cells (using mito‑targeted restriction endonucleases) will recapitulate age‑associated epigenetic changes and SASP expression within two weeks.

Experimental Design

• Model: Primary mouse embryonic fibroblasts (MEFs) subjected to irradiation‑induced senescence; aged (24‑month) C57BL/6J mice treated with mitochondrially targeted BAX inhibitor peptide or vehicle.
• Interventions: (a) BAX/BAK siRNA, (b) cGAS KO via CRISPR, (c) STING pharmacological inhibitor (C-176).
• Readouts: Whole‑genome bisulfite sequencing for epigenetic age, ATAC‑seq for chromatin accessibility, immunofluorescence for H3K9me3/H3K27ac, SASP cytokine panel (ELISA), and mitochondrial respiration (Seahorse).
• Controls: Non‑targeting siRNA, wild‑type littermates, and mitochondria‑targeted catalase to rule out ROS‑specific effects.

Potential Outcomes

If our hypothesis holds, inhibiting mtDNA release or downstream cGAS‑STING signaling will (1) attenuate epigenetic age acceleration, (2) restore heterochromatin at LADs, and (3) diminish SASP despite persistent mtDNA damage. Conversely, if nuclear epigenetic changes proceed unchanged, mtDNA release would be deemed a parallel inflammatory driver rather than a chromatin reprogrammer.

Implications

Confirming that mtDNA release epigenetically reprograms the nucleus would reposition the mitochondrial genome as an upstream regulator of aging, shifting focus from nuclear‑centric edits to preserving mitochondrial membrane integrity or blocking cytosolic DNA sensing as a primary longevity strategy.